Skip to main content
. 2017 May 16;18(5):1062. doi: 10.3390/ijms18051062

Table 6.

Studies of inhaled tobramycin in NCFB patients with P. aeruginosa present in sputum.

Study/Year Preparation Dose/Frequency Duration Patient Population Key Outcomes after Treatment
Barker 2000 [95] TSI 300 mg/BID 28 days n = 74 Decrease in bacterial load
Scheinberg 2005 [96] TSI 300 mg/BID 14 days on, 14 days off (3 cycles) n = 41 Improvements in respiratory symptoms
Drobnic 2005 [97] TSI 300 mg/BID 6 months n = 30 Improvement in the number of admissions and days of admission to the hospital
Bilton 2006 [98] Oral ciprofloxacin or oral ciprofloxacin + TSI 750 mg/BID (ciprofloxacin)
300 mg/BID (TSI)
2 weeks n = 53, with an acute exacerbation Double therapy resulted in a trend towards greater rates of eradication, but cure rates and relapse rates were similar in both groups

BID, twice a day; TSI, tobramycin solution for inhalation.